SSY Group (2005) investor relations material

Executive summary

• Revenue for H1 2026 reached HK$2,361 million, up 9.9% year-over-year, driven by strong growth in high-end and large-volume infusion solutions and bulk pharmaceuticals.

• Net profit attributable to equity shareholders rose 13.0% to HK$320.3 million, with EPS at HK$0.1107, up from HK$0.0962.

• Interim dividend per share increased 10% year-over-year to HK$0.055, with payout ratio stable at ~50%.

• The Group maintained growth and a sound liquidity position despite a complex macroeconomic and industry environment.

• Product mix optimization and expanded market share supported performance domestically and internationally.

Financial highlights

• Gross profit margin was 41.2%, slightly down from 41.5% year-over-year.

• Operating profit rose 20.1% to HK$445 million, with operating margin at 18.9%.

• EBITDA increased 11.8% year-over-year and 62.0% sequentially, with margin at 28.8%.

• Cash and cash equivalents stood at HK$1,856 million as of June 30, 2026, up 9.8% year-over-year.

• Net assets at HK$8,136.1 million; net assets per share at HK$2.76.

Outlook and guidance

• Focus on expanding high-end infusion and export markets, accelerating new product launches, and integrating innovation, product, supply, and value chains.

• R&D to emphasize complex generics and innovative drugs, targeting 109 new product approvals by year-end and 55 new product specifications in H2 2026.

• Continued investment in intelligent manufacturing, infrastructure, and supply chain integration.